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Abstract
There is a region with a high risk for esophageal squamous 
cell carcinoma (ESCC) in the northeast of Iran. Previous 
studies suggest that hereditary factors play a role in the high 
incidence of cancer in the region. We selected 22 functional 
variants (and 130 related tagSNPs) from 15 genes that have 
been associated previously with the risk of ESCC. We 
genotyped a primary set of samples from 451 Turkmens (197 
cases and 254 controls). Seven of 152 variants were associated 
with ESCC at the P = 0.05 level; these single nucleotide 
polymorphisms were then studied in a validation set of 549 
cases and 1,119 controls, which included both Turkmens and 
non-Turkmens. The association observed for a functional 
variant in ADH1B was confirmed in the validation set, and 
that of a tagSNP in MGMT, the association was borderline 
significant in the validation set, after correcting for multiple 
testing. The other 5 variants that were associated in the 
primary set were not significantly associated in the validation 
set. The histidine allele at codon 48 of ADH1B gene was 
associated with a significantly decreased risk of ESCC in the 
joint data set (primary and validation set) under a recessive 
model (odds ratio, 0.41; 95% confidence interval, 0.29-0.76; 
P = 4 x  10-4). The A allele of the rs7087131 variant of MGMT 
gene was associated with a decreased risk of ESCC under a 
dominant model (odds ratio, 0.79; 95% confidence interval, 
0.64-0.96; P = 0.02). These results support the hypothesis that 
genetic predisposition plays a role in the high incidence of 
ESSC in Iran. [Cancer Res 2009;69(20):7994–8000] 
 
Introduction
Worldwide, 462,000 new cases of esophageal cancer are 
diagnosed annually (1). Seventy-five percent of affected individuals 
die within a year of diagnosis and the 5-year survival rate is only 
10% to 16% (1). The incidence of esophageal cancer varies greatly 
between populations and across geographic regions. The east part 
of Golestan Province in northeastern Iran is a region with a very 
high risk of esophageal cancer, but the causative factors remain 
 
elusive. The annual incidence rate exceeds 100/100,000 (2, 3), 
although the rate has declined over the last three decades (4). 
Turkmens constitute half of the population in this region and 
Persians, Turks, Sistanies, Balouches, and Kurds constitute the 
other half (referred to here as non-Turkmens). 
Esophageal cancer is of two main histologic types: squamous cell 
carcinoma and adenocarcinoma. Esophageal squamous cell 
carcinomas (ESCC) constitute >90% of esophageal cancers among 
both Turkmens and non-Turkmens in eastern Golestan (5). We 
have recently shown that, among Turkmens, there is a strong 
familial component to esophageal cancer (6). The first gene found 
to contribute to the burden of esophageal cancer in Iran was 
BRCA2 (7). Protein-truncating mutations in BRCA2 are associated 
with an increased risk of esophageal cancer among Turkmens. 
However, because only 8% of the cases in the region carry a 
deleterious BRCA2 mutation (7), it is likely that other genes are 
involved. 
Turkmens are believed to descend from Turkic tribes who 
migrated from the Altai Mountains (on the border of China and 
Mongolia) to northern Iran (8). A population at high risk for ESCC 
is also present in China (9) and the two high-risk populations might 
share common susceptibility alleles. Based on this hypothesis, we 
propose that the genes that have been reported previously to be 
associated with ESCC in the high-risk Chinese population (10, 11) 
are candidate genes among Turkmens. Initially, we focused on 
Turkmens because this is the largest ethnic group in the region and 
they are believed to be genetically homogeneous. However, we also 
studied a similar number of non-Turkmens from the same region. 
We studied 15 different genes that are involved in DNA repair, cell 
cycle control, and the metabolism of alcohol, folate, and 
carcinogens. 
Materials and Methods 
Study Subject 
This report is a component of the Gastric and Esophageal Malignancies 
in Northern Iran Project (5, 12, 13), which is under way in Gonbad, the 
second largest city of Golestan Province, in northeastern Iran and in 
Ardabil, the largest city in Ardabil Province in northwestern Iran. The 
project is directed by the Digestive Disease Research Center of the Tehran 
University of Medical Sciences in collaboration with the National Cancer 
Institute, the IARC, and the University of Toronto. Cases and controls were 
collected between August 1, 2001 and May 15, 2008. The diagnosis of ESCC 
was confirmed for all cases by upper gastrointestinal endoscopy and by 
pathologic evaluation of tumor biopsies. The study protocol was approved 
by the ethics committees of the Digestive Disease Research Center, the 
National Cancer Institute, and the IARC. 
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We employed a two-stage design. In the first stage, we genotyped a total 
of 152 variants in 197 Turkmen cases and 254 Turkmen controls (the 
primary sample set). In the second stage, we genotyped the most promising 
variants identified from the primary sample set in 549 more cases and 1,119 
more controls, including both Turkmens and non-Turkmens (the validation 
sample). The entire set of samples genotyped in this study is referred to as 
the joint sample set. 
Cases. A total of 746 cases was enrolled in this study. There were 281 
Turkmens and 220 non-Turkmens ESCC cases from Gonbad City. Non-
Turkmen cases included Persians (n = 114), Turks (n = 59), Sistanies (n = 
28), Balouches (n = 9), and Kurds (n = 10). In addition, we enrolled 245 
Turkish cases from Ardabil, a city in northwestern Iran with intermediate 
rates of ESCC (13). The mean age at diagnosis was 63.6 years (range, 25-89 
years); 380 cases (50.9%) were male and 366 cases (49.1%) were female. 
Epidemiologic data included smoking status, use of opium and alcohol, and 
a family history of cancer. The primary set of cases consisted of the first 197 
Turkmens who were available for testing. The remaining 549 cases 
composed the validation set (84 Turkmens and 465 non-Turkmens). 
Controls. One thousand three hundred seventy-three controls were 
recruited to the study: 244 were Turks from Ardabil City, 811 were Turkmen 
from Gonbad City, and 318 were non-Turkmen from Gonbad City [Persians 
(n = 133), Turks (n = 78), Sistanies (n = 79), Balouches (n = 19), and Kurds 
(n = 9)]. Eight hundred ninety-eight controls were patients referred to local 
hospitals for a reason other than cancer and 475 controls were healthy 
individuals enrolled from the Golestan cohort study (12). Controls had no 
personal history of cancer. The mean age for controls was 55.2 years (range, 
24-90 years); 700 (51.0%) were male and 673 (49.0%) were female. The 
primary set of controls consisted of the first 254 Turkmens who were 
available for testing. The remaining 1,119 controls composed the validation 
set (557 Turkmens and 562 non-Turkmens). Characteristics of the total 746 
cases and 1,373 controls are presented in Table 1. 
Candidate Genes 
Genes were selected based on literature review of the previously reported 
ESCC-associated variants, which mostly were from Chinese population. 
Four genes were involved in DNA repair ERCC2 (XPD), XRCC1, hOGG1, and 
MGMT; four genes were involved in cell cycle control: CCND1 (cyclin D1), 
CDKN2A (p16), TP53 (p53), and TMPRSS11A (ECRG1); four genes coded for 
carcinogen-metabolizing enzymes: CYP1A1, CYP2E1, GSTP1, and NAT2; two 
genes coded for alcohol-metabolizing enzymes: ADH1B and ALDH2; and 
Table 1. Subject characteristics of the ESCC cases and 
controls 
Variable 
Total n 
Age, mean (range) 
Gender, n (%) 
Male 
Female 
Ethnicity, n (%) 
Turkmen 
Turk 
Persian 
Sistani 
Balouch 
Kurd 
Ever smoker, n (%) 
Yes 
No 
Ever opium user, n (%) 
Yes 
No 
Cases 
746 
63.6 (25-89) 
380 (50.9) 
366 (49.1) 
281 (37.7) 
304 (40.7) 
114 (15.3) 
28 (3.7) 
9 (1.2) 
10 (1.3) 
200 (27.9) 
516 (72.1) 
158 (29.1) 
382 (70.9) 
Controls 
1,373 
55.2 (24-90) 
700 (51.0) 
673 (49.0) 
811 (59.0) 
322 (23.5) 
133 (9.7) 
79 (5.8) 
19 (1.4) 
9 (0.6) 
339 (25.0) 
1018 (75.0) 
239 (20.2) 
943 (79.8) 
P 
— 
<0.001 
1.0 
<0.001 
0.14 
<0.001 
one gene coded for a folate-metabolizing enzyme: MTHFR. The role of these 
genes and their variants in esophageal cancer has been reviewed (10, 11). 
For each gene, at least one functional variant has been reported in the 
literature to be associated with ESCC (10, 11, 14). These variants include 
Asp312Asn (rs1799793) and Lys751Gln (rs13181) from ERCC2 gene; Arg399Gln 
(rs25487) from XRCC1 gene; Cys (rs1052133) from hOGG1 gene;Ser326
Leu74Phe (rs12917) and Lys178Arg (rs2308327) from MGMT gene; c.870A>G 
(rs9344) from CCND1 gene; Ala148Thr (rs3731249) from CDKN2A gene; 
Arg72Pro (rs1042522) from TP53 gene; Arg293Gln (rs353163) from 
TMPRSS11A (ECRG1) gene; Val (rs1048943) from CYP1A1 gene; Ile462
c.-1019C>T (rs2031920) from CYP2E1; Ile105Val (rs1695) from GSTP1 gene; 
Tyr94Tyr (rs1041983), Ile114Thr (rs1801280), Leu161Leu (rs1799929), 
Arg197Gln (rs1799930), and Gly286Glu (rs1799931) from NAT2 gene; Arg48His 
(rs1229984) from ADH1B gene; Glu487Lys (rs671) from ALDH2 gene; and 
Ala222Val (rs1801133) and Glu429Ala (rs1801131) from MTHFR gene. 
Three slow-metabolizing alleles of M1, M2, and M3 were reported for 
NAT2 gene. Variants Ile114Thr and Leu161Leu constitute allele M1, variants 
Arg197Gln and Tyr94Tyr constitute allele M2, and variant Gly286Glu is named 
allele M3 (15). 
tagSNP Selection 
Within populations, it is believed that single nucleotide polymorphisms 
(SNP) are distributed along chromosomes in haplotype blocks; therefore, 
genotyping of one or more SNPs, which are characteristic of a haplotype 
block, will capture the important information for the additional SNPs in 
that block. These SNPs are in linkage disequilibrium with the genotyped 
SNPs and are called tagSNPs. Genotype data from the Chinese population of 
the HapMap project (ref. 16; Rel21/phase II) were used for selecting tagSNPs 
to cover the genomic region of each gene, including 5 kbp in each 5¶ and 3¶ 
ends to cover the regulatory regions of the genes. Haploview software (17) 
was used for selecting tagSNPs. Aggressive tagging with using two- and 
three-marker haplotypes, LOD score threshold of 3.0 for multimarker 
testing, and r 2 threshold of 0.8 were employed for tagging procedure. 
Genomic regions of all 15 candidate genes encompass 705 kbp of the human 
genome. There are 635 SNPs with minor allele frequency of >1% in the 
Chinese population of the HapMap project. One hundred forty-one tagSNP 
were selected to capture 594 SNPs (94% of the total common SNPs) with 
mean r 2 of 0.98 in 152 tests (Table 2). 
SNP Genotyping 
We initially tested the 152 SNPs in a primary set of 197 cases and 
254 controls. From the 141 tagSNPs selected for study, 11 were among 
the functional variants mentioned above and 130 were additional. All SNPs 
were genotyped in germ-line DNA of all samples of the primary set of cases 
and controls. iPLEX chemistry on a matrix-assisted laser desorption/ 
ionization—time-of-flight MassARRAY System (Sequenom) was used for 
genotyping the 152 SNPs in eight reactions. The procedures were done 
according to the manufacturer’s standard protocol. SNPs that showed 
association with ESCC in the primary set of samples (P < 0.05) were 
combined and a new assay design was done to genotype them in a single 
reaction. ESCC-associated SNPs identified in the primary set of samples 
were genotyped in the germ-line DNA of the validation set of samples 
at the second stage. Ten percent blinded quality-control samples were 
included in each plate; the concordance rates ranged from 98% to 100%. 
The average genotyping call rate was 98% (ranging from 95% to 100%). Two 
ESCC-associated SNPs were failed for genotyping in the primary set of 
samples; they were genotyped using TaqMan assay on ABI 7500 fast real-
time system (Applied Biosystems). Genotyping of the primary set and 
validation set were done in Analytical Genetics Technology Centre of the 
University of Toronto and Genome Quebec Innovation Centre, respectively. 
Statistical Analysis 
The permutation version of the exact test was done to test for Hardy-
Weinberg equilibrium. All genotypes were first studied in the primary 
sample set. Based on the results of the primary set, variants were selected 
for genotyping in the validation set. Haplotype analysis using expectation 
maximization algorithm (18) was used for comparing SNPs tagged by 
multiple markers. The significance level of a = 0.05 was used for all 
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Table 2. Number of tagSNPs genotyped in this study along with the number of the SNPs captured with these tagSNPs for 
each gene 
No. Gene Chromosome Size (kbp)* Genotyped tagSNPs, n Captured SNPs, n (%)
c 
Mean max r 2 
1 ADH1B 4 10 3 4/4 (100) 1.00 
2 ALDH2 12 53 10 22/23 (95) 0.95 
3 CCND1 11 23 2 2/2 (100) 1.00 
4 CDKN2A 9 18 6 8/8 (100) 0.99 
5 CYP1A1 15 16 1 1/1 (100) 1.00 
6 CYP2E1 10 22 6 27/34 (79) 0.97 
7 ECRG1 4 63 9 49/54 (90) 0.99 
8 ERCC2 19 29 8 18/20 (90) 0.97 
9 GSTP1 11 13 4 12/12 (100) 0.99 
10 MGMT 10 310 49 321/332 (96) 0.95 
11 MTHFR 1 30 8 35/36 (97) 0.99 
12 NAT2 8 20 10 40/46 (86) 0.94 
13 OGG1 3 27 5 5/5 (100) 1.00 
14 TP53 17 29 6 7/14 (50) 1.00 
15 XRCC1 19 42 14 43/44 (97) 0.93 
Total 705 141 594/635 (94) 0.98 
*Size of the gene, including 5 kbp, at each end for covering gene regulatory regions. 
cThe number of the SNPs with minor allele frequency >1% identified in the Chinese population of the HapMap project and the proportion of these SNPs 
that is captured by the genotyped tagSNPs in this study are shown for each gene. 
comparisons in the primary sample set (the P values of the comparisons 
from the primary set were not adjusted for multiple testing). Because the 
direction of association in the validation set was based on the primary set 
results, a one-sided test was used for the comparisons in the validation set. 
In the validation set, the P values of the comparisons were corrected for 
multiple testing using the Bonferroni approach. For those variants that were 
independently confirmed in the validation set, the genotypes of the primary 
set and the validation set were combined to form a joint sample set. All 
case-control comparisons were adjusted for age and ethnicity using 
multivariate logistic regression. Ethnicity was defined as Turkmen, Turk, 
Persian, Sistani, Balouch, or Kurd. 
To exclude the possibility that there were technical errors in genotyping 
between the typing of subjects in the primary and validation sets, we re­
genotyped all the 7 variants genotyped in the validation set in the primary 
sample set using the genotyping assay used for the validation sample set. 
The concordance rate of the genotyping results was 97%. 
Figure 1. Eigenvectors of the first two 
principle components with the largest 
Eigenvalues plotted for the primary sample 
set using genotyping data of 152 SNPs. 
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Table 3. Genotyping results of the variants confirmed in the validation set 
Gene, variant Primary set, n (%) Validation set, n (%) Joint set, n (%) 
Cases 
(197) 
Controls 
(254) 
OR* P* Cases 
(549) 
Controls 
(1,119) 
OR
c 
P
b 
Cases 
(746) 
Controls 
(1,373) 
OR
c 
P
c 
ADH1B, Arg48His 
Arg/Arg 129 (66.5) 145 (57.3) 1.00 1.00 361 (65.8) 682 (61.0) 1.00 1.00 490 (65.7) 827 (60.2) 1.00 1.00 
Arg/His 59 (30.5) 96 (37.9) 0.66 0.04 173 (31.5) 375 (33.5) 0.91 1.00 232 (31.1) 471 (34.3) 0.84 0.10 
His/His 6 (3.0) 12 (4.8) 0.70 0.17 15 (2.7) 61 (5.5) 0.59 0.0014 21 (2.8) 73 (5.3) 0.63 0.0002 
Dominant 0.64 0.03 0.82 0.31 0.77 0.01 
Recessive 0.61 0.33 0.35 0.0014 0.41 0.0004 
MGMT, rs7087131 
G/G 137 (70.6) 171 (68.7) 1.00 1.00 417 (76.2) 786 (70.3) 1.00 1.00 554 (74.8) 957 (70.0) 1.00 1.00 
G/A 56 (28.9) 65 (26.1) 1.05 0.82 115 (21.0) 305 (27.3) 0.74 0.07 171 (23.1) 370 (27.1) 0.81 0.06 
A/A 1 (0.5) 13 (5.2) 0.30 0.002 15 (2.8) 27 (2.4) 0.96 1.00 16 (2.1) 40 (2.9) 0.78 0.09 
Dominant 0.89 0.59 0.76 0.10 0.79 0.02 
Recessive 0.10 0.002 0.98 1.00 0.63 0.13 
*P and OR were adjusted for age using multivariate logistic regression analysis. 
cP and OR were adjusted for age and ethnicity using multivariate logistic regression analysis. 
bP is based on one-sided test and adjusted for age and ethnicity using multivariate logistic regression analysis and for multiple testing using Bonferroni 
correction. 
The possibility that there is spurious population stratification in the 
Turkmens was addressed by principle component analysis using the 
Eigenstrat method (19) for identifying any population stratification in the 
primary sample set, which we had genotypes of 130 tagSNPs plus 22 
functional variants for them. By plotting the Eigenvectors of the first two 
principle components with the largest Eigenvalues for the cases and the 
controls (Fig. 1), it appears that population stratification was not present. 
All analyses were done by SNP Variation Suit version 7 (Golden Helix). 
Results 
Initially, we genotyped 152 SNPs in a primary set of 197 cases 
and 254 controls. These were the first samples to be collected in the 
course of the project and all subjects were Turkmen. These SNPs 
included 22 functional variants of 15 genes and 130 tagSNPs from 
these genes. The results of the 17 functional variants and 3 slow-
metabolizing alleles of NAT2 gene in the primary set of 451 
samples are shown in Supplementary Table S1. The frequencies of 
the minor alleles of all variants, except one (ALDH2 Glu487Lys), 
were >1%. All were in Hardy-Weinberg equilibrium. 
In addition, we selected and genotyped 130 tagSNPs of 15 
different genes in the primary set of samples. These SNPs had not 
been studied previously in ESCC. Eight tagSNPs had minor allele 
frequencies of <0.01 and 3 tagSNPs were not in Hardy-Weinberg 
equilibrium. These 11 tagSNPs were excluded from the analysis. 
The remaining 119 tagSNPs were analyzed in the primary set of 197 
cases and 254 controls. 
Two functional variants showed associations with ESCC in the 
primary sample set with P values < 0.05 (the Arg48His variant from 
ADH1B gene and c.870A>G from CCND1). Five tagSNPs, from five 
different genes, also showed significant associations in the primary 
set. These 7 SNPs (2 functional variants and 5 tagSNPs) were then 
genotyped in the validation set of samples. The results are reported 
separately for the primary set, the validation set, and the joint set 
(Table 3). Results were reported in the form of odds ratios (OR) for 
the three genotype classes, with the most common homozygous 
genotype being the reference class. The cases and controls were 
different with regards to age and ethnic group (Table 1); therefore, 
all ORs were adjusted for age and ethnic group. Results were also 
reported assuming dominant and recessive models. 
The strongest association was observed with the His allele of the 
Arg48His variant of ADH1B gene. This allele was associated with a 
decreased risk of ESCC under a recessive model (Table 3). 
Compared with those who carried no His allele, those who carried 
two His alleles were at reduced risk (OR, 0.63; P = 0.0002; 95% 
confidence interval, 0.34-0.93). 
This association with the rs7087131 variant of MGMT gene was 
borderline significant in the validation set after adjusting for 
multiple testing (Table 3). In the combined set, the A allele of the 
rs7087131 variant of MGMT gene was associated with a decreased 
risk of ESCC under a dominant model (OR, 0.79; 95% confidence 
interval, 0.64-0.96; P = 0.02). For the other 5 variants, the 
associations were failed to be confirmed in the validation set 
(Table 4). 
Discussion 
We studied 22 different functional variants of 15 genes, which 
were previously reported to be associated with ESCC. Notably, the 
ORs reported for these variants in the earlier studies were typically 
z2.0 (11). Given that the frequencies of the minor alleles of these 
variants in our population were almost all above 0.1 (Supplemen­
tary Table S1), the power of our study to detect ORs above 2.0 
exceeded 90%. However, of the 22 variants tested, only two 
polymorphisms (ADH1B Arg48His and CCND1 c.870A>G) showed 
significant associations at the P = 0.05 level in the primary sample 
set and ADH1B Arg48His was then confirmed in the validation set. 
In the joint sample set, the Arg48His allele was protective under 
a recessive model (OR, 0.41; 95% confidence interval, 0.29-0.76; 
P = 4  x 10 -4; Table 4). ADH1B is one of seven different genes that 
encode five different classes of alcohol dehydrogenase (ADH) 
enzymes. These enzymes are involved in the oxidation of alcohol 
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groups of a variety of substrates. ADH class I, which is responsible 
for the oxidation of ethanol to acetaldehyde, is a homodimer or 
heterodimer of three related subunits (a, h, and g) encoded by 
ADH1A, ADH1B, and ADH1C, respectively (20). All ADH enzymes 
use NAD+/NADH as their oxidizing cofactor. The arginine residue 
at codon 48 of ADH1B is in close contact with its cofactor and 
seems to have a crucial role on modulating the ethanol oxidizing 
capability of the protein. When the arginine is replaced by histidine 
at this codon, the enzyme activity increases by 70- to 80-fold (20). 
In a rodent model, ADH1B, which has proline at this codon, is not 
capable of oxidizing ethanol (21). 
In previous studies, the Arg allele of ADH1B consistently has been 
reported to increase the risk of ESCC by 1.6- to 4-fold among alcohol 
drinkers compared with individuals with two His alleles (10, 11, 22). 
The suggested mechanism is that alcohol and acetaldehyde persist 
for a longer time in the circulation of individuals with the Arg allele, 
who are slow metabolizers. These individuals tend to experience 
less flushing on exposure to alcohol and are prone to alcoholism 
(23). We confirmed that the presence of the Arg allele at codon 48 of 
the ADH1B protein increases the risk of ESCC by 2.4-fold in 
comparison with two His alleles (P = 4  x 10 -4). Considering that 
only 4.5% of our study subjects were alcohol drinkers, this finding 
suggests that in Iran the association is not due to metabolism of 
alcohol per se. Our observation is contrary to other studies that 
report no association between the Arg48His variant of the ADH1B 
gene and the risk of ESCC among nondrinkers (22, 24, 25). Most 
studies that showed the association of Arg48His variant of ADH1B 
with ESCC in alcohol drinkers also report an association between 
the Glu487Lys variant of ALDH2 and esophageal cancer (11). The 
ALDH2 protein with lysine residue at codon 487 is catalytically 
inactive and cannot metabolize acetaldehyde, a known carcinogen 
(23). We did not observe this association in Iran. 
Our data suggest that, in Northern Iran, ESCC may be related 
to an environmental factor other than ethanol but is also 
metabolized by ADH1B. 1-Methylpyrene (1-MP) is a candidate 
for such an environmental factor. 1-MP is a carcinogenic 
polycyclic aromatic hydrocarbon (PAH), which is metabolized 
to 1-hydroxymethylpyrene (1-HMP) by cytochrome P450 en­
zymes. 1-HMP could be activated by sulfotransferases to 
1-sulfooxymethylpyrene (1-SMP), which is capable of forming 
Table 4. Genotyping results of the five initially ESCC-associated variants that were not confirmed in the validation set 
Gene, variant Primary set, n (%) Validation set, n (%) 
Cases (197) Controls (254) OR* P* Cases (549) Controls (1,119) OR
c 
P
b 
ALDH2, rs886205 
T/T 99 (51.0) 107 (43.2) 1.00 1.00 289 (52.8) 564 (50.4) 1.00 1.00 
T/C 80 (41.2) 100 (40.3) 0.87 0.52 209 (38.2) 449 (40.1) 0.92 1.00 
C/C 15 (7.8) 41 (16.5) 0.62 0.004 49 (9.0) 106 (9.5) 0.97 1.00 
Dominant 0.73 0.11 0.93 1.00 
Recessive 0.42 0.005 1.00 1.00 
CCND1, c.870A>G 
A/A 53 (27.2) 79 (31.6) 1.00 1.00 158 (28.8) 355 (31.8) 1.00 1.00 
A/G 83 (42.6) 116 (46.4) 1.09 0.72 276 (50.3) 550 (49.2) 1.02 1.00 
G/G 59 (30.2) 55 (22.0) 1.30 0.04 115 (20.9) 213 (19.0) 1.04 1.00 
Dominant 1.27 0.26 1.05 1.00 
Recessive 1.61 0.03 1.09 1.00 
ECRG1, rs6552135 
A/A 78 (40.2) 69 (27.8) 1.00 1.00 167 (31.2) 339 (40.0) 1.00 1.00 
A/G 71 (36.6) 117 (47.2) 0.50 0.002 252 (47.1) 524 (47.9) 1.00 1.00 
G/G 45 (23.2) 62 (25.0) 0.80 0.09 116 (21.7) 231 (21.1) 0.99 1.00 
Dominant 0.55 0.004 1.00 1.00 
Recessive 0.94 0.80 0.98 1.00 
ERCC2, rs3916874 
G/G 143 (73.0) 152 (60.8) 1.00 1.00 379 (69.2) 739 (66.4) 1.00 1.00 
G/C 47 (24.0) 87 (34.8) 0.56 0.008 152 (27.7) 337 (30.3) 0.93 1.00 
C/C 6 (3.0) 11 (4.4) 0.80 0.39 17 (3.1) 37 (3.3) 0.92 1.00 
Dominant 0.57 0.007 0.92 1.00 
Recessive 0.76 0.60 0.85 1.00 
TP53, rs1625895 
G/G 112 (57.4) 167 (66.8) 1.00 1.00 318 (58.1) 689 (61.6) 1.00 1.00 
G/A 73 (37.4) 75 (30.0) 1.53 0.04 197 (36.0) 365 (32.6) 1.07 1.00 
A/A 10 (5.1) 8 (3.2) 1.35 0.23 32 (5.9) 65 (5.8) 1.00 1.00 
Dominant 1.55 0.03 1.07 1.00 
Recessive 1.57 0.36 0.99 1.00 
*P and OR were adjusted for age using multivariate logistic regression analysis. 
cOR was adjusted for age and ethnicity using multivariate logistic regression analysis. 
bP is based on one-sided test and adjusted for age and ethnicity using multivariate logistic regression analysis and for multiple testing using Bonferroni 
correction. 
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DNA adducts, but most of 1-HMP is inactivated by ADH1B and 
excreted in urine and does not form DNA adducts (26, 27). 
PAHs have been shown to be esophageal carcinogens in both 
animal and human studies. In a 2-year feeding study in mice, a 
dose-response relationship was shown between benzo[a]pyrene 
intake and ESCC incidence (28). Occupational exposure to PAHs in 
Sweden was reported to double the risk of ESCC (29). Other lines of 
evidence that support the contribution of PAHs in the pathogenesis 
of ESCC come from a high-risk region in China and include high 
urinary levels of PAH metabolites in residents (30), increased 
concentrations of PAHs in cooked and uncooked foods in the 
region (28), and the presence of PAH-DNA adducts in ESCC tissue 
samples of patients (31). 
PAHs require metabolic activation to become carcinogens. 
Purely aromatic PAHs, such as benzo[a]pyrene, are activated via 
the diol-epoxide pathway (32), but alkylated PAHs, such as 1-MP, 
are metabolized by an alternative pathway named the aralkylating 
hydrocarbon pathway (33). In this pathway (Fig. 2), 1-MP is 
hydroxylated to 1-HMP by cytochrome P450 enzymes such as 
CYP1A1 (34). 1-HMP subsequently forms reactive sulfuric acid ester 
(1-SMP) by the action of sulfotransferases (35, 36). 1-SMP forms 
DNA adducts and has been shown to be mutagenic in rats (33) and 
in Salmonella typhimurium (37). 1-SMP is also reacts with 
glutathione and is excreted in urine as methylpyrenyl mercapturic 
acid (MPMA). The urine MPMA constitutes only 2% of the 
administrated 1-HMP to rats; 80% of it is excreted as free 1­
pyrenylcarboxylic acid (1-PCA) and its glucuronic acid or other 
conjugates (26). 1-PCA is an inactivate metabolite of 1-HMP, which 
has been oxidized by ADH1B (27). Therefore, ADH1B competes 
with sulfotransferases for the metabolism of 1-HMP and ADH1B 
activity decreases the formation of DNA adducts. If ADH1B is the 
major enzyme for the inactivation of 1-HMP, then other substrates 
of ADH1B are expected to interfere with inactivation of 1-HMP and 
increase the amount of its activated metabolite. This has been 
exhibited by concurrent administration of 1-HMP and ethanol to 
rats, thereby enhancing the hepatic level of PAH-DNA adducts by 
15-fold (26). The competition of ethanol with 1-HMP for oxidation 
by ADH1B could also explain the synergistic carcinogenic effect of 
alcohol and cigarette smoke (which is rich in 1-MP, the precursor of 
1-HMP; ref. 27). It is possible that individuals with two slow-
metabolizing Arg alleles at codon 48 of ADH1B gene do not 
inactivate 1-HMP as efficiently as those who carry one or more His 
alleles at this codon. In this case, more 1-HMP would be available 
for conversion to 1-SMP by sulfutransferases; consequently, more 
DNA adducts would be formed (Fig. 2). 
The rs7087131 variant of MGMT was also found to be associated 
with ESCC under a dominant model. However, this association was 
of borderline significance. O6-methylguanine is formed by alkylating 
agents such as nitrosamines, which are associated with an increased 
risk of ESCC (38). O6-methylguanine has been found in the epithelial 
cells of the esophagus of individuals living in the high-risk region 
of China (39). Unrepaired O6-methylguanine tends to pair with 
thymine and introduces G:C to A:T transitions during cell 
replication (40). O 6-methylguanine-DNA methyltransferase 
(MGMT) repairs O6-methylguanine by transferring the methyl 
group to a cysteine residue at codon 145 of the enzyme (41). Binding 
of methyl group to the cytosine residues of MGMT is an irreversible 
reaction, and after repairing each single O6-methylguanine, the 
protein is ubiquitylated and degraded and needs to be replaced by a 
new protein. Therefore, it is expected that cells with low expression 
of MGMT cannot repair O6-methylguanine efficiently. Low expres­
sion of MGMT in cells can result from either promoter hyper­
methylation of the gene or by cis-acting nucleotide polymorphisms, 
which change the binding sites of key regulatory factors (42). A 
group of SNPs at the 5¶ half of the gene were described to be in 
association with MGMT activity in WBC (42). The rs7087131 variant 
is also located at the 5¶ half of the MGMT gene in the intronic region 
between exons 2 and 3 and directly or indirectly might affect 
expression level of the gene and contribute to the risk of ESCC in 
Iran. In our study, the substitution of G by A nucleotide in this 
variant decreased the risk of ESCC under a dominant model (OR, 
0.79; 95% confidence interval, 0.64-0.96; P = 0.02). 
There are several limitations to our study. The sample size was 
relatively small and we did not have sufficient power to detect 
associations of a modest size, for example, ORs of <1.5. The primary 
data set was composed of Turkmens, and if an association were to 
be present only in non-Turkmen, it would not be discovered using 
this strategy. Similarly, if an association were present only in 
Turkmens, it would fail to be confirmed in the validation set. We 
have collected data on family history for most of the cases, but 
because of the high fatality rate of esophageal cancer, a DNA 
sample was available for the proband only. 
Figure 2. Suggested metabolic pathway 
for 1-MP. 1-MP is first metabolized to 
1-HMP by cytochrome P450 (CYP450 ) 
enzymes. The majority (f80%) of 1-HMP 
is detoxified by alcohol dehydrogenase 
(ADH1B ) to 1-formylpyrene (1-FP ) and 
then to 1-PCA by aldehyde dehydrogenase 
(ALDH ). 1-PCA and its glucoronic acid 
conjugates are excreted in urine. Some of 
(f20%) 1-HMP are transformed to 1-SMP 
of which the majority form DNA adducts 
and some of it (f2%) are detoxified by 
nucleophile glutathione and form MPMA. 
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In conclusion, this study extends our earlier observations that 
genetic factors play an important role in the high incidence of 
esophageal cancer in the northeast of Iran. A strong and significant 
association was seen with the Arg48His allele of ADH1B gene 
among both Turkmens and non-Turkmens. In several previous 
studies, this variant was associated with the risk of ESCC, primarily 
among alcohol drinkers (10, 11, 22). Interestingly, in this study, the 
variant is related to the risk of ESCC in alcohol nondrinkers, 
suggesting that other carcinogens might be causative. 
It is important that this observation be confirmed in larger series 
of patients. To date, we have strong evidence that both BRCA2 and 
ADH1B contribute to the burden of esophageal cancer in Northern 
Iran, but the known variants in these two genes are not sufficient to 
explain the high incidence of esophageal cancer in the region, or 
the high familial relative risk, and further studies are needed. 
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